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(95 % CI 0.3–1.0; P = 0.04) by independent and investiga-
tor review, respectively. Mgn1703 significantly improved 
PFS measured from the start of induction therapy versus 
placebo on independent (HR 0.49; 95 % CI 0.26–0.94; 
P = 0.03) and investigator review (HR 0.50; 95 % CI 0.31–
1.02; P = 0.02). Overall survival (OS) data remain imma-
ture (HR 95 %; 95 % CI 0.3–1.5; P = 0.29) with 28/43 
patients alive after a medium follow-up of >17 months. 
Retrospective subgroup analysis showed a significant 
effect of Mgn1703 on PFS versus placebo in patients with 
greater than median tumour size reduction and normalised 
carcinoembryonic antigen concentrations following induc-
tion therapy, and in patients with elevated activated nKt 
cells ≥3.08 %. adverse events were mild to moderate 
Abstract 
Purpose this phase II study evaluated the synthetic 
Dna-based immunomodulator and toll-like receptor 9 
agonist Mgn1703 as maintenance treatment in metastatic 
colorectal carcinoma (mCRC).
Methods Fifty-nine patients with mCRC and disease con-
trol after standard first-line chemotherapy were randomised 
to Mgn1703 60 mg (N = 43) or placebo (N = 16).
Results the hazard ratio (HR) for the primary endpoint 
[progression-free survival (PFS) from the start of mainte-
nance] was 0.56 (95 % CI 0.29–1.08; P = 0.07) and 0.55 
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and limited to injection-site reactions or linked to general 
immune system activation.
Conclusions Mgn1703 maintenance treatment was well 
tolerated and appears to induce durable and prolonged PFS 
and disease control in a subgroup of patients with mCRC 
following induction therapy. activated nKt cells may be a 
predictive biomarker for selecting patients likely to benefit 
more from Mgn1703.
Keywords Mgn1703 · Immunomodulator · tlR9 
agonist · Colorectal cancer · Maintenance
Introduction
In recent years, a number of agents have been developed 
with the aim of harnessing the inherent anti-cancer capa-
bilities of the immune system. Most efforts have focused 
on the activation of adaptive immunity, as seen with ipil-
imumab—a cytotoxic t lymphocyte-associated antigen 4 
inhibitor active in melanoma—and with other checkpoint 
inhibitors that target the programmed cell death 1 pathway 
(Hodi et al. 2010; Robert et al. 2011; topalian et al. 2012; 
tournigand et al. 2012; Brahmer et al. 2012). an additional 
immunomodulatory approach involves stimulation of 
innate immunity. Mgn1703 is a novel, synthetic, dumb-
bell-shaped, covalently closed Dna molecule (Weihrauch 
et al., submitted), which activates the innate immune sys-
tem via toll-like receptor 9 (tlR9) (Fig. 1). the tlR9 
receptor is expressed on plasmacytoid dendritic cells (pDC) 
and B cells and recognises non-methylated cytosine–gua-
nine dinucleotide (Cg) motifs in bacterial, viral and mito-
chondrial Dna (Schmidt et al. 2006a; Krieg 2002; Kanzler 
et al. 2007; ahmad-nejad et al. 2002). tlR agonists can 
stimulate innate antitumour mechanisms, including activa-
tion of natural killer t (nKt) cells, monocytes and mac-
rophages, and induction of cytokines (Kanzler et al. 2007; 
Carpentier et al. 2006; Pashenkov et al. 2006; Friedberg 
et al. 2005). tlR agonists containing non-methylated Cg 
motifs have exhibited limited, transient adverse effects 
and some efficacy in clinical trials in various tumour types 
(Kanzler et al. 2007; Carpentier et al. 2006; Pashenkov 
et al. 2006; Friedberg et al. 2005).
Mgn1703 has been investigated as adjuvant therapy in 
two trials (Weihrauch et al. 2005; Wittig et al. 2001). In 
the first, Mgn1703 was used in combination with chem-
oimmunotherapy in patients with metastatic colorectal 
carcinoma (CRC) (Weihrauch et al. 2005); in the second, 
Fig. 1  Mechanism of action of Mgn1703. ADCC antibody-depend-
ent cell-mediated cytotoxicity, BCR B-cell receptor, IFN interferon, 
IL interleukin, mDC myeloid dendritic cells, MHC major histocom-
patibility complex, NK cell natural killer cell, NKT cell natural killer 
t cell, pDC plasmacytoid dendritic cells, TAA tumour-associated 
antigens, TCR t-cell receptor, TLR9 toll-like receptor 9
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patients with metastatic solid tumours of colon, renal cell, 
or melanoma origin received autologous gene-modified 
cells with adjuvant Mgn1703 (Wittig et al. 2001). In 
both cases, regimens were well tolerated with mild, tran-
sient side effects, although Mgn1703 doses were low 
(Weihrauch et al. 2005; Wittig et al. 2001). More recently, 
a phase I trial showed that twice-weekly subcutaneous 
applications of single-agent Mgn1703 (up to 60 mg) were 
well tolerated in 28 patients with metastatic solid tumours 
(Weihrauch et al., submitted). Six patients had stable dis-
ease (prolonged in three cases), and one with refractory 
CRC had a partial response.
the current study evaluated Mgn1703 as maintenance 
treatment in patients with metastatic CRC who had disease 
control after induction chemotherapy. Failure of a different 
tlR9 agonist to improve outcomes in advanced non-small 
cell lung cancer when added to chemotherapy suggests that 
the supportive immune response initiated by tlR9 agonists 
may firstly require release of tumour-associated antigens 
(Hirsh et al. 2011). a decreased tumour burden together 
with a chemotherapy-free interval allowing recovery of 
immune cells may also facilitate a more effective immune 
response (Hirsh et al. 2011). this type of immunotherapy 
may therefore prove successful when given sequentially 
after chemotherapy. treatment for metastatic CRC has 
improved significantly over the last two decades (Chu 
2012), and the potential value of maintenance therapy is 
being extensively investigated (Strickler and Hurwitz 2012; 
Díaz-Rubio et al. 2012; tournigand et al. 2012; Koeberle 
et al. 2013; Koopman et al. 2014).
IMPaCt, a randomised, placebo-controlled, double-
blind, phase II study, evaluated the efficacy and safety of 
subcutaneous Mgn1703 (60 mg twice-weekly) as main-
tenance therapy following successful first-line induction 
therapy in metastatic CRC. this was the first placebo-
controlled trial to prospectively investigate the impact of 
an immunomodulator as maintenance therapy in metastatic 
CRC and was based on the hypothesis that patients with 
disease control could benefit from immunotherapy.
Methods
Study population
the study recruited males or females aged over 18 years 
with histologically confirmed CRC that had been radio-
logically confirmed before starting first-line therapy as 
unresectable and advanced disease (american Joint Com-
mittee on Cancer stage IV). to be eligible, patients were 
also required to have previous first-line therapy with fluo-
ropyrimidine plus irinotecan or oxaliplatin, with or without 
bevacizumab, for 4.5–6 months (treatment with oxaliplatin 
or irinotecan for at least 3 months); disease control after 
first-line therapy, defined as objective response or stable 
disease; at least one measurable lesion according to revised 
Response evaluation Criteria in Solid tumors (ReCISt) 
(eisenhauer et al. 2009); eastern Cooperative Oncology 
group (eCOg) performance status 0 or 1; and adequate 
bone marrow, liver and kidney function. Patients were 
excluded if they had tumour progression after first-line 
therapy; more than one previous line of systemic chemo-
therapy for metastatic CRC; known central nervous sys-
tem metastases; history of autoimmune disease or immune 
deficiency; active or uncontrolled infections; transfusion-
dependent anaemia; concurrent chronic systemic immune 
therapy or immunosuppressant medication including ster-
oid treatment; chemotherapy or immunotherapy within the 
2 weeks before randomisation or radiotherapy 6 months 
before randomisation. all patients gave written, informed 
consent.
Study design and treatments
this randomised trial took place at 22 centres in austria, 
France, germany and Russia (Clinicaltrials.gov identifier: 
nCt01208194). the primary endpoint was progression-
free survival (PFS), measured from the date of randomisa-
tion to progression on maintenance therapy. Secondary end-
points included PFS measured from the start of induction 
therapy to progression on maintenance; overall survival 
(OS) from randomisation and start of induction therapy; 
objective response rate per ReCISt during maintenance 
treatment; safety; and biomarkers for efficacy, including 
immunological response. Patients were randomised in a 2:1 
ratio to Mgn1703 60 mg or placebo, both given subcuta-
neously twice-weekly until disease progression, unaccepta-
ble toxicity, appearance of exclusion criteria, withdrawal of 
patient consent, or death. the study was approved by the 
relevant Investigational Review Boards or ethics Commit-
tees and was run in accordance with the Declaration of Hel-
sinki and good Clinical Practice guidelines.
Randomisation and masking
a randomisation list was generated using a standard 
computer programme and was designed in blocks of six 
patients. treatment was allocated centrally; the spon-
sor provided sites with a patient number, which uniquely 
identified the treatment to be administered. the study was 
double-blind, with one copy of the complete randomisa-
tion code held by Mologen ag until study end and a sec-
ond provided to a Data Safety Monitoring Board (DSMB). 
Investigators received a sealed random code envelope for 
each individual patient number, which was opened only in 
an emergency.
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assessments
tumour response was assessed by computed tomography 
scan using the revised ReCISt (eisenhauer et al. 2009) at 
baseline, at weeks 12, 18 and 24, and every 12 weeks thereaf-
ter. assessment of scans by local investigators was confirmed 
by review by two independent radiologists. Regular safety 
assessments included physical examination, haematology 
and clinical chemistry tests, vital signs, electrocardiogram 
and eCOg performance status. adverse events were moni-
tored regularly and graded using the national Cancer Institute 
Common toxicity Criteria for adverse events version 4.0.
Immunotherapy biomarker study
Whole blood samples were collected for the analysis of 
immunotherapy biomarkers at baseline and after 3, 6, 12 
and 24 weeks, or at the end of study visit if after 24 weeks. 
Blood samples were shipped to the central laboratory 
(labor Berlin gmbH, germany) at room temperature 
and were analysed by fluorescence activated cell sorting 
(FaCS) within 24 h. Frequency and activation status of the 
following immune cells were assessed by FaCS: mono-
cytes, B lymphocytes, t lymphocytes, nKt cells, nK cells, 
plasmacytoid dendritic cells and myeloid dendritic cells.
Data analyses
Sample size was estimated using nquery version 7.0; 
the calculation assumed that PFS would increase from 
3 months with placebo to 6 months with Mgn1703, that 
at 6 months, the hazard ratio (HR) for progression would 
be 0.5 and an alpha level of 0.05 with 80 % power. an esti-
mated 129 patients were required (86 and 43 patients ran-
domised to Mgn1703 and placebo, respectively).
the primary analysis of efficacy endpoints was on an 
intent-to-treat basis. efficacy was also analysed in a sub-
group based on the per-protocol population but which 
excluded patients with abnormal prognostic laboratory 
parameters at baseline and/or the first visit on study. Safety 
analyses used the as-treated population (all patients who 
received at least one dose of study medication, with treat-
ment assignments designated according to the actual study 
treatment received). the DSMB monitored safety data 
and advised on whether the trial could be continued. One 
interim analysis was planned after 60 patients had been 
treated for 4.5 months. PFS and OS were estimated using 
Kaplan–Meier methods and medians for each variable pre-
sented with 95 % confidence intervals (CIs). PFS and OS 
were compared between treatment groups using the log-
rank test. the proportion of patients in each group who 
achieved an objective tumour response, defined as the sum 
of complete and partial responses, was calculated.
to identify patient subgroups most likely to obtain ben-
efit from Mgn1703 with respect to PFS, pre-planned anal-
yses of immunotherapy biomarkers and patient character-
istics at baseline were performed. Cox regression analysis 
and receiver operating characteristic analysis were used to 
identify biomarkers and optimal cut-off levels appropriate 
for the comparison of PFS. Methodology of the baseline 
characteristics analysis is described in the appendix.
Role of the funding source
the study sponsor participated in study design and data col-
lection and interpretation. this report was written by the 
corresponding author with contribution and review by all 
co-authors, including those employed by the sponsor. the 
corresponding author had full access to all study data and had 
final responsibility for the decision to submit the report for 
publication.
Results
Patients, demographics and baseline characteristics
Between June 2010 and May 2012, 59 patients were 
randomised to receive Mgn1703 (N = 43) or placebo 
(N = 16) (Fig. 2). Patient baseline demographics and char-
acteristics were generally well balanced between treatment 
groups (table 1).
Following a planned interim analysis, recruitment was 
halted in May 2012 before reaching the recruitment target 
of 129 patients. the primary reason for stopping the trial 
was the slow recruitment, which could not be accelerated, 
despite several attempts by the sponsor.
at the time of this analysis, median duration of follow-
up for the Mgn1703 group was 17.7 months (95 % CI 
Fig. 2  trial profile. ITT intent to treat
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13.8–19.6) and for placebo was 16.5 months (95 % CI 
15.3–21.6). Median treatment duration was 3.2 months 
(range 1–26) and 2.9 months (range 1–12), respectively. 
all patients had discontinued; the most common reason 
for discontinuation was disease progression, reported in 
31 (72 %) and 14 (88 %) patients in the Mgn1703 and 
placebo groups, respectively. eight patients discontinued 
study for clinical signs of relapse (such as fever, increasing 
biomarkers and local obstruction) that could not be con-
firmed by the independent review. Four patients continued 
to receive treatment with Mgn1703 following the study.
efficacy and response
Hazard ratio (HR) for investigator assessment of the pri-
mary endpoint was 0.55 (95 % CI 0.3–1.0; P = 0.04), with 
Mgn1703 maintenance treatment associated with durable 
PFS in some patients (Fig. 3a); median PFS was 2.8 months 
(95 % CI 2.8–4.1) with Mgn1703 and 2.6 months (95 % 
CI 2.5–2.8) with placebo. HR for an independent review 
assessment of the primary endpoint was 0.56 (95 % CI 
0.29–1.08; P = 0.07) (see Fig. 3 footnote).
When measured from the start of induction therapy, PFS 
was significantly improved with Mgn1703 versus placebo 
both with independent and investigator assessment (HR 
0.49; 95 % CI 0.26–0.94; P = 0.03 and HR 0.50; 95 % CI 
0.31–1.02; P = 0.02; Fig. 3b and footnote). HR for PFS 
from randomisation in the protocol-defined subgroup popu-
lation with ‘good risk’ characteristics was 0.52 (95 % CI 
0.26–1.04; P = 0.0526), corresponding to a median PFS 
of 3.0 months (95 % CI 2.8–6.6) with Mgn1703 (N = 38) 
and 2.8 months (95 % CI 2.5–2.8) with placebo (N = 15).
Overall survival (OS) data were still immature after a 
median follow-up of over 17 months (appendix Fig. S1a), 
with more than 50 % of patients censored. Measured from 
randomisation, median OS was 22.6 months (95 % CI 
14.9–not reached [nR]) with Mgn1703 and 15.1 months 
(95 % CI 10.6–nR) with placebo (HR 0.63; 95 % CI 0.3–
1.5; P = 0.2886; appendix Fig. S1a). Median OS from the 
start of induction therapy was 26.3 months (95 % CI 21.0–
nR) and 21.2 months (95 % CI 16.5–nR) for Mgn1703 
and placebo, respectively (HR 0.65; 95 % CI 0.3–1.6; 
P = 0.3339; appendix Fig. S1b).
three patients in the Mgn1703 group had a confirmed 
objective tumour response (objective response rate 7.0 %) 
during maintenance treatment, observed 3, 9 and 9 months 
after randomisation. at the time of this analysis, all three 
patients, plus a fourth patient in complete remission after 
induction chemotherapy, remain stable without relapse, 
having been on treatment for 16–30 months. One placebo-
treated patient had a response (objective response rate 
6.3 %) after 3 months (response duration, 6 months).
analyses of immunological biomarkers
Forty-six patients were included in a pre-planned analysis 
of potential immunological biomarkers (32 and 14 patients 
from the Mgn1703 and placebo groups, respectively). In 
patients with high (≥3.08 %) activated nKt cell counts 
at baseline, Mgn1703 was associated with significantly 
greater PFS than placebo (HR 0.27; 95 % CI 0.14–0.82; 
P = 0.007; Fig. 4a). this phenomenon was not observed in 
patients with activated nKt cell counts below this cut-off 
(HR 0.47; 95 % CI 0.14–1.6; P = 0.16; Fig. 4b).
evidence for the activation of the immune system in 
patients treated with Mgn1703 was provided by observed 
increases in the proportion of activated monocytes and 
pDC in these patients (appendix).
analyses of baseline patient characteristics predictive 
for progression-free survival
In the analyses of baseline patient characteristics, two 
of three factors included in the Cox proportional hazards 
model had statistically significant effects on PFS: reduction 
Table 1  Patient demographic and disease characteristic at baseline 
(intent-to-treat cohort)
CR complete response, ECOG eastern Cooperative Oncology group, 
PR partial response, SD stable disease
a
 assessed before induction therapy
 
b
 Difference to 100 %: missing values
Characteristic Mgn1703 Placebo
(N = 43) (N = 16)
age, median (range) 65.0 (39–80) 67.5 (44–80)
gender: male/female, n (%) 21/22 (49/51) 8/8 (50/50)
eCOg performance status: 0/1, n (%) 29/14 (67/33) 10/6 (63/37)
Site of primary tumour, n (%)
 Colon 24 (56) 9 (56)
 Rectum 13 (30) 6 (17)
 Both 6 (14) 1 (6)
Site of metastatic diseasea, n (%)
 liver only 15 (35) 6 (38)
 lung only 4 (9) 1 (6)
 Other 24 (56) 9 (56)
Surgery: primary in situ 12 (28) 5 (31)
Median duration (range) of induction 
therapy, months
5.4 (3–10) 5.3 (4–7)
Prior induction regimen, n (%)
 FOlFOX/XelOX + bevacizumab 16 (37) 7 (44)
 FOlFIRI/XelIRI + bevacizumab 21 (49) 8 (50)
 FOlFOX/XelOX alone 6 (14) 1 (6)
Best response to induction therapy, n (%)
 CR/PR 29 (67)b 14 (88)
 SD 13 (30) 2 (12)
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in tumour size at the end of induction therapy (>median 
versus ≤ median; HR 1.015 [95 % CI 1.002–1.029; 
P = 0.0238]) and carcinoembryonic antigen (Cea) con-
centration at the end of induction therapy (<upper limit of 
normal [Uln] versus ≥ Uln; HR 0.326 [95 % CI 0.159–
0.668; P = 0.0022]). Resection of primary tumour (yes 
versus no) was not significant (HR 0.851; 95 % CI 0.385–
1.884; P = 0.6921).
Fig. 3  PFS by treatment group from a randomisation and b start of induction therapy (investigator assessmenta). CI confidence interval, HR haz-
ard ratio, mPFS median progression-free survival, PFS progression-free survival
Fig. 4  PFS from randomisation by treatment group for patients with nKt cell counts ≥3.08 % (a) or <3.08 % (b). CI confidence interval, HR 
hazard ratio, NKT natural killer t, PFS progression-free survival
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In patients with a reduction in tumour size following 
induction therapy greater than the median reduction, PFS 
was significantly longer with Mgn1703 than placebo but 
this effect of Mgn1703 was not observed in patients with 
a reduction in tumour size less than median (appendix 
Fig. S2a). Similarly, in patients with Cea concentrations 
within the normal range, PFS was significantly longer with 
Mgn1703 than placebo but no such effect was observed in 
patients with Cea above the normal range (appendix Fig. 
S2b). PFS was also significantly extended with Mgn1703 
in patients with response after induction but not in patients 
with stable disease (appendix Fig. S2c). these data should 
be treated with some caution, however, since patient num-
bers are small, particularly in the placebo group.
Safety and tolerability
In the Mgn1703 and placebo groups, respectively, 79 
and 38 % of patients experienced any treatment-emergent 
adverse event; overall incidence of grade 3/4 adverse events 
was 26 and 13 %, respectively. treatment-related adverse 
events were reported in 33 and 12.5 % of Mgn1703- and 
placebo-treated patients, respectively, while grade 3/4 
adverse events regarded as treatment-related were rare (2 
and 8 %, respectively; n = 1 in each group). One patient 
discontinued Mgn1703 because of an adverse event (sen-
sory neuropathy; no discontinuations in the placebo group).
grade 3/4 treatment-emergent adverse events observed 
in the Mgn1703 group included ileus (n = 4), hyperten-
sion (n = 2), worsening of hypertension (n = 2), neu-
tropenia, aspartate aminotransferase increase, sensory 
polyneuropathy and sepsis (each n = 1). the case of poly-
neuropathy was considered possibly related to Mgn1703, 
but was more likely to have been associated with previous 
oxaliplatin chemotherapy. among five patients with serious 
adverse events, two had ileus, a third had ileus with sep-
sis and another had ileus with alimentary toxicosis; none 
of these events were considered related to treatment. the 
fifth patient was admitted to hospital with atypical pneu-
monia (grade 2), which was considered possibly related to 
Mgn1703 treatment. In the placebo group, grade 3 adverse 
events comprised papular exanthema, food poisoning and 
coxarthrosis (each n = 1); there were no grade 4 adverse 
events and none were considered serious.
treatment-related adverse events of interest because 
of the mode of action of Mgn1703 are summarised in 
table 2. these were typically mild to moderate (grade 1 or 
2) and in the Mgn1703 group included most commonly 
flu-like symptoms and injection-site reactions. Mild local 
reactions (pain, redness, itching or induration) occurred 
in 77 and 6 % of patients in the Mgn1703 and placebo 
groups, respectively. these symptoms were limited at the 
site of injection and did not result in treatment interruption.
Discussion
the IMPaCt trial showed that Mgn1703 maintenance 
treatment was well tolerated and appears to induce durable 
PFS and disease control in selected patients with advanced 
CRC following induction therapy.
Findings from the study reflect the complications and 
challenges faced in assessing clinical response to immuno-
therapies. In the primary endpoint analysis, Kaplan–Meier 
curves separated after the median point; similar findings 
have been reported in other recent studies in metastatic 
CRC, for example, in populations with mixed KRAS muta-
tion status treated with epidermal growth factor recep-
tor inhibitors (Saif and Shah 2009; Ramos et al. 2008). 
therefore, the activity of Mgn1703 may be limited to a 
specific subpopulation of patients who achieve a prolonged 
response to treatment. Indeed, results from the secondary 
analyses indicate that three possible subgroups existed. 
Firstly, the greatest benefit with Mgn1703 was observed 
in patients who achieved shrinkage of their tumour after 
induction chemotherapy. this is consistent with the theory 
that immunomodulatory treatment is more likely to be 
successful in patients with relatively low tumour burden. 
Similarly, normal Cea values after induction therapy also 
had predictive value. Finally, results from the immuno-
logical biomarker analysis reported a significant effect of 
Mgn1703 on PFS relative to placebo in patients with lev-
els of activated nKt cells ≥3.08 % but not in those with 
levels below this cut-off. activated nKt cells may be a 
potential biomarker for selecting patients more likely to 
benefit from Mgn1703 treatment.
two assessments of response were used in the trial (inves-
tigator and independent review). Primary endpoint results 
with the two assessment methods were similar, although 
P-values decreased with the investigator assessment 
Table 2  Summary of treatment-emergent adverse events of particular 
interest due to Mgn1703 mechanism of action
AE adverse event, ANA antinuclear antibody
ae, number of  
patients (%)
Mgn1703 (N = 43) Placebo (N = 13)
grade 1/2 grade 3/4 grade 1/2 grade 3/4
Flu-like symptoms 6 (13.9) – 1 (7.7) –
general pain 4 (9.3) – 1 (7.7) –
general rash, itching, 
paraesthesia
4 (9.3) – – 1 (7.7)
Injection-site reaction 2 (4.6) – 1 (7.7) –
atypical pneumonia 2 (4.6) – – –
Polyneuropathy 1 (2.3) 1 (2.3) – –
ana increased 1 (2.3) – 1 (7.7) –
Fatigue 1 (2.3) – – –
Hypertension 1 (2.3) – – –
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relative to independent review (0.04 versus 0.07), reflecting 
a decrease in statistical uncertainty caused by a reduction in 
the number of censored patients. In the independent review, 
13 patients were censored (eight local relapses as assessed 
by investigators could not be confirmed on scans by the 
independent review). the investigator assessment included 
these eight patients so that only five patients were censored. 
Such inaccurate identification of relapse is indicative of the 
challenges involved in measuring responses to immunother-
apy. Immunomodulators are associated with unique patterns 
of response versus conventional therapies. In studies of ipil-
imumab, for example, disease regression was sometimes not 
seen for several months and, in other cases, lesion growth 
was observed due to immune-related inflammation not dis-
ease progression (Weber et al. 2012).
Immune-related response criteria have now been defined 
(Wolchok et al. 2009), although traditional ReCISt crite-
ria, which may not detect all responses to immunotherapy 
(Hales et al. 2010), were used in the current trial. there-
fore, in subsequent studies on Mgn1703, immune-related 
response criteria may be more appropriate.
Data from several randomised trials investigating mainte-
nance treatment for metastatic CRC with agents such as beva-
cizumab have recently been reported (Díaz-Rubio et al. 2012; 
tournigand et al. 2012; Koeberle et al. 2013; Koopman et al. 
2014). Interpretation of these data is complex, as all the trials 
differ in design and in how the maintenance or de-escalation 
phase is managed. therefore, many questions remain regard-
ing whether, and in what form, maintenance treatment should 
be used in this setting. Comparison of PFS data from the 
current trial and other trials of maintenance therapy is made 
difficult by the different assessment schedules employed. In 
the study reported here, the first assessment was performed at 
month 3 to allow patients to receive adequate immunomodu-
latory therapy; this is reflected in the steep decay of the upper 
portions of the Kaplan–Meier curves. With regard to other 
immunomodulators, the current data appear to be consistent 
with observations from some trials showing no effect in terms 
of median PFS but lasting benefit in some patients (Chung 
et al. 2010; Kirkwood et al. 2010). It may be of interest to 
observe, as with other immunomodulators, whether mature 
OS results for Mgn1703 point to a broader activity than seen 
on the shorter-term PFS endpoint.
Structural and preclinical studies have shown that 
Mgn1703 is a potent tlR9 agonist with limited capac-
ity for interactions with molecules outside its target structure 
(Schmidt et al. 2006b, 2008; Kapp et al., submitted). In addi-
tion to this specificity, the relevant cellular activation profile 
of Mgn1703 is distinct to that of other tlR9 agonists, such 
as PF-3512676, which failed to show benefit compared with 
chemotherapy alone in two phase III trials in nSClC (Hirsh 
et al. 2011; Manegold et al. 2012). additional immunotherapy 
approaches have been investigated in patients with tumour 
types other than CRC. these include agents that target spe-
cific immune regulatory checkpoints and increase the endog-
enous antitumour immune response. For example, ipilimumab 
which binds to Ctla-4, has been shown to result in 2-year 
survival rates of 23.5 % in patients with metastatic melanoma 
(Hodi et al. 2010). the majority of adverse events with ipili-
mumab are consistent with the proposed mechanism of action 
and can be severe, and long-lasting (Hodi et al. 2010). Other 
immune checkpoint inhibitors have been developed to target 
the programmed cell death 1 receptor and prevent t-cell inac-
tivation, with studies investigating their potential in melanoma 
and nSClC (Pardoll and Drake 2012). the combination of 
Mgn1703 with a checkpoint inhibitor could offer a poten-
tially synergistic immunotherapeutic approach in this setting.
Safety data for Mgn1703 were in accordance with 
those from the phase I trial (Weihrauch et al., submitted). 
Mgn1703 was generally well tolerated, with most drug-
related adverse events being mild or moderate. Common 
adverse events included injection-site reactions, fever and 
fatigue. good tolerance of Mgn1703 was confirmed by 
the lack of treatment interruption despite therapy for up 
to 30 months in patients experiencing prolonged response. 
In general, the tolerability profile of Mgn1703 appears 
similar to that of therapeutic vaccines such as sipuleucel-t, 
rather than the checkpoint inhibitors (Frohlich 2012).
Overall, the results from this trial are encouraging and 
suggest a potential role for tlR9-targeted immunoactiva-
tion with Mgn1703 in maintenance therapy of metastatic 
CRC after an effective first-line regimen inducing a tumour 
response. It is important, however, that the current results 
are not over-interpreted because of the very limited sam-
ple size due to the early study termination. a randomised, 
phase III trial of Mgn1703 in the first-line/maintenance 
setting in patients with metastatic CRC is planned.
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